Corcept Therapeutics Incorporated $CORT Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 111.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 507,967 shares of the biotechnology company’s stock after buying an additional 268,155 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.48% of Corcept Therapeutics worth $19,404,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CORT. Royal Bank of Canada boosted its holdings in Corcept Therapeutics by 18.9% during the first quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock worth $1,757,000 after buying an additional 2,444 shares in the last quarter. Amundi purchased a new position in Corcept Therapeutics during the first quarter worth approximately $450,000. NewEdge Advisors LLC acquired a new stake in Corcept Therapeutics in the first quarter valued at approximately $518,000. Cetera Investment Advisers increased its position in shares of Corcept Therapeutics by 32.9% in the second quarter. Cetera Investment Advisers now owns 11,129 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 2,755 shares in the last quarter. Finally, New York State Common Retirement Fund increased its position in shares of Corcept Therapeutics by 19.1% in the second quarter. New York State Common Retirement Fund now owns 42,363 shares of the biotechnology company’s stock valued at $3,109,000 after buying an additional 6,800 shares in the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Corcept Therapeutics

In related news, Director G Leonard Baker, Jr. acquired 100,000 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were purchased at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the acquisition, the director owned 1,146,631 shares in the company, valued at $37,999,351.34. The trade was a 9.55% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joseph K. Belanoff sold 26,198 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the completion of the sale, the chief executive officer owned 2,918,326 shares of the company’s stock, valued at $146,120,582.82. This trade represents a 0.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 86,198 shares of company stock worth $3,552,769 over the last three months. Insiders own 20.80% of the company’s stock.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: Several plaintiff firms and alert services (ClaimsFiler, Kaplan Fox, Bronstein Gewirtz, Schall, Glancy, Pomerantz, Rosen, etc.) remind investors of the April 21 lead‑plaintiff deadline and encourage affected shareholders to contact counsel; these notices increase publicity and bring more potential claimants into the case. ClaimsFiler Alert
• Neutral Sentiment: Multiple firms issued nearly identical deadline alerts over the last 48 hours (Kaplan Fox, Hagens Berman, Schall, Rosen, Glancy, Pomerantz), consolidating media attention around the litigation and the specified class period (Oct 31, 2024–Dec 30, 2025). Kaplan Fox / Globe & Mail
• Negative Sentiment: A plaintiff firm (Hagens Berman) highlights allegations the company made misstatements concerning FDA data — the complaint ties the suit to regulatory setbacks, which, if proven, could support larger investor claims and potential damages. This raises the prospect of material exposure beyond legal fees. Hagens Berman Alert
• Negative Sentiment: At least one alert frames the securities suit as following an FDA rejection and a recent federal court patent loss, signaling multiple catalysts behind investor claims (regulatory and IP setbacks increase downside risk to future revenues). Such combined regulatory/IP exposure typically amplifies potential settlement sizes and investor concern. GlobeNewswire / Hagens Berman
• Negative Sentiment: Coverage notes the original securities complaint was filed in February 2026; continued media and firm outreach suggests the litigation will remain an active headline risk through the April deadline and into any lead‑plaintiff selection, potentially affecting trading sentiment and valuation multiples. TipRanks summary

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Wolfe Research upgraded Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday, March 26th. Zacks Research cut shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. HC Wainwright decreased their price objective on shares of Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, March 25th. Truist Financial upgraded shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Canaccord Genuity Group boosted their target price on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.67.

Corcept Therapeutics Stock Performance

CORT opened at $42.49 on Friday. The stock has a market capitalization of $4.52 billion, a PE ratio of 51.82 and a beta of 0.25. Corcept Therapeutics Incorporated has a one year low of $28.66 and a one year high of $91.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. The business’s 50 day moving average price is $37.80 and its 200 day moving average price is $59.61.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.13). The business had revenue of $202.13 million for the quarter, compared to analyst estimates of $254.94 million. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.Corcept Therapeutics’s revenue was up 11.1% compared to the same quarter last year. During the same period last year, the business earned $0.26 EPS. As a group, equities research analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Corcept Therapeutics Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.